Specialized logistics critical for delivering next-generation cell and gene therapies

The article explains that personalized medicines such as cell and gene therapies are transforming treatment for rare diseases and cancers.

Unlike conventional drugs, these therapies are often made for individual patients, are irreplaceable, and highly sensitive to temperature and timing, creating unprecedented logistical hurdles.

Companies like Marken and UPS Healthcare are developing specialized logistics networks to protect the products during manufacturing, transport, and administration, aiming to preserve efficacy.

Any disruption can result in loss of the therapy and delay for the patient, highlighting the high stakes and need for reliable supply chain solutions.